TREATMENT PROFILE AND CLINICAL OUTCOMES OF COVID-19 PATIENT WITH DIABETES MELLITUS IN INDRAPURA FIELD HOSPITAL INDONESIA

Abstract

Diabetes mellitus is one of the leading causes morbidity and mortality in adult with COVID-19 worldwide and definitive treatment has not yet been established. To describe treatment and clinical outcomes of COVID-19 patient with Diabetes mellitus. In this descriptive study, we reviewed the electronic medical records of patients at Indrapura Field Hospital, Surabaya, Indonesia from May 2020 to February 2021. A total of 260 patients who had confirmed COVID-19 with Diabetes Mellitus were included. Demographic data, laboratory data, therapy, and clinical outcomes were collected and analyzed. This study showed that 140 patients were males (53.8%) and the mean age was 51 years old. Hypertension was the main comorbid disease (47,7%), followed by obesity class I (38,1%). Cough (47.7%) and fever (23.8%) were most common clinical symptoms. Based on medical history, 189 (72.7%) patients had uncontrolled diabetes mellitus and some of them came with moderate and severe COVID-19 (5,8% and 10,5%). Anti-viral agent was not prescribed in this centre. During admission all patients received vitamin. Symptomatic treatment was given to some patients such as oxygen (11.9%), antitussive (47.3%), and antipyretic (24.7%). Regarding the treatment of diabetes mellitus, 150 patients (57,6%) received oral antihyperglycemia, 75 patients (28.8%) received insulin, and 22 patients (8.4%) received both. The average fasting blood glucose level on admission improved before discharged (210.75mg/dL vs182.03 mg/dL) and similarly the average 2-hour postprandial blood glucose level (271,19 mg/dL vs 222,01 mg/dL). There were 202 patients (77.7%) stayed in the hospital more than 10 days. At the end of treatment, 229 patients (88.1%) were confirmed to had recovered from COVID-19, 29 patients (11.2%) were referred for desaturation. No patient died during treatment. Symptom management, supportive treatment, and antihyperglycemia drugs were given during hospitalization and most of patients recovered form COVID-19 after treatment.